Everything below concerns Cyclic AMP. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-08. Numbers and descriptions here follow the published literature rather than marketing material.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
The AToFMS allows for the determination of mixing state, or distribution of chemical species, within individual particles. These mixing states are important in the determination of climate and health impact of aerosols. The schematic of a typical AToFMS is shown to the right. The overall structure of ATOF instruments is; sampling, sizing, and the mass analyzer region. The inlet system is similar to the AMS by using the same aerodynamic focusing lens, but it has smaller orifices because of its analysis of single particles. In the sizing region particle passes through the first continuous solid state laser that generates an initial pulse of scattered light. Then the particle passes through the second laser that is orthogonal to the first and produces a pulse of scattered light. The light is detected by a photomultiplier (PMT) that is matched up to each laser. Using the transit times between the two detected pulses and the fixed distance the velocity and size of each particle is calculated. Next the particles travel through to the mass analyzer region where it is ionized by a pulsed LDI laser, which is timed to hit the particle as it reaches the center of the ion extraction region. Once ionized, the positive ions are accelerated towards the positive ToF section and the negative ions are accelerated towards the negative ToF section where they are detected.
== Adverse effects == The most common side effects for guselkumab are upper respiratory tract infections, headache, injection site reactions, joint pain, diarrhea, gastroenteritis, fungal skin infections and herpes simplex infections.
In hemolysis (accelerated breakdown of red blood cells), associated jaundice is caused by the hemoglobin metabolite bilirubin, and the circulating hemoglobin can cause kidney failure. Some mutations in the globin chain are associated with the hemoglobinopathies, such as sickle-cell disease and thalassemia. Other mutations, as discussed at the beginning of the article, are benign and are referred to merely as hemoglobin variants. There is a group of genetic disorders, known as the porphyrias that are characterized by errors in metabolic pathways of heme synthesis. King George III of the United Kingdom was probably the most famous porphyria sufferer. To a small extent, hemoglobin A slowly combines with glucose at the terminal valine (an alpha aminoacid) of each β chain. The resulting molecule is often referred to as Hb A1c, a glycated hemoglobin. The binding of glucose to amino acids in the hemoglobin takes place spontaneously (without the help of an enzyme) in many proteins, but whether it serves a useful purpose is unknown. However, as the concentration of glucose in the blood increases, the percentage of Hb A that turns into Hb A1c increases. In diabetics whose glucose usually runs high, the percent Hb A1c also runs high. Because of the slow rate of Hb A combination with glucose, the Hb A1c percentage reflects a weighted average of blood glucose levels over the lifetime of red cells, which is approximately 120 days. The levels of glycated hemoglobin are therefore measured in order to monitor the long-term control of the chronic disease of type 2 diabetes mellitus (T2DM).
In 1939, the first commercial pressure cookers were released onto the market, mostly designed for steaming vegetables. Sanders bought one and modified it into a pressure fryer, which he then used to fry chicken. The new method reduced production time to be comparable with deep frying while, in the opinion of Sanders, retaining the quality of pan-fried chicken.
=== Therapeutics === The small size and stability profile of Affimers combined with their human origin confer drug-like properties. This may represent advantages over antibodies in terms of tissue penetration, for example in solid tumours where Avacta are developing PD-L1 inhibitors as alternatives to Opdivo and Yervoy, though requires half life modification to prevent rapid excretion through the kidney. Affimers can be conjugated to form multimers for the design of therapeutics. Examples include the production of multi-specific Affimer molecules to albumin binders to increase their half-life in vivo and for use as the targeting moiety in chimeric receptors or modified to carry a toxin in Affimer-drug conjugates. Affimers as therapeutics are in discovery and preclinical development to tackle cancer, both via CAR-T cell therapy and as checkpoint inhibitors. Early studies using ex vivo human samples showed low immunogenicity associated with the Affimer scaffold, at levels comparable to a marketed antibody therapeutic. Furthermore, initial preclinical studies showed good efficacy and tolerability of the anti-PDL1 immuno-oncology Affimers in mice. It is anticipated that IND filing for the first Affimer therapeutic will occur in 2023.
Sources: en.wikipedia.org
The only extensive area of flat land in Powys is the region northeast of Welshpool. The county is named after the Kingdom of Powys, which was a Welsh successor state, petty kingdom and principality that emerged during the Middle Ages following the end of Roman rule in Britain.
The family's first home in exile was Wartegg Castle in Rorschach, Switzerland, a property owned by the Bourbon-Parmas. However, the Swiss authorities, worried about the implications of the Habsburgs living near the Austrian border, compelled them to move to the western part of the country. The next month, the Habsburgs moved to Villa Prangins, near Lake Geneva, where they resumed a quiet family life. This abruptly ended in March 1920 when, after a period of instability in Hungary, Miklós Horthy was elected regent. Charles was still technically King (as Charles IV) but Horthy sent an emissary to Prangins advising him not to go to Hungary until the situation had calmed. After the Trianon Treaty Horthy's ambition soon grew. Charles became concerned and requested the help of Colonel Strutt to get him into Hungary. Charles twice attempted to regain control, once in March 1921 and again in October 1921. Both attempts failed, despite Zita's staunch support (she insisted on travelling with him on the final dramatic train journey to Budapest). Charles and Zita temporarily resided at Tata Castle, the home of Count Esterházy, until a suitable permanent exile could be found. Malta was mooted as a possibility, but was declined by Lord Curzon, and French territory was ruled out given the possibility of Zita's brothers intriguing on Charles's behalf. Eventually, the Portuguese island of Madeira was chosen. On 31 October 1921, the former Imperial couple were taken by rail from Tihany to Baja, where the Royal Navy monitor HMS Glowworm was waiting.
Feringa and co-workers used this approach in their design of a molecule that can repeatably perform 360° rotation. The full rotation of this molecular motor takes place in four stages. In stages A and C rotation of the aryl moiety is restricted, although helix inversion is possible. In stages B and D the aryl can rotate with respect to the naphthalene with steric interactions preventing the aryl from passing the naphthalene. The rotary cycle consists of four chemically induced steps which realize the conversion of one stage into the next. Steps 1 and 3 are asymmetric ring opening reactions which make use of a chiral reagent in order to control the direction of the rotation of the aryl. Steps 2 and 4 consist of the deprotection of the phenol, followed by regioselective ring formation.
== Primary indexes == In addition to the primary indices listed below, Russell publishes Value and Growth versions of each U.S. index. This divides each index roughly in half, separating companies classified as value stocks from those classified as growth stocks. Companies can appear in both the value and growth versions of an index, though the total number of shares between the value and growth versions will equal the number in the main index. The primary indices are:
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.